Core Viewpoint - The company,透景生命, has invested 68 million yuan in 惠和生物, acquiring a 9.21% stake, aligning with its strategic focus on the full chain of autoimmune disease management from diagnosis to treatment [1][2]. Investment Details - The investment of 68 million yuan is aimed at supporting 惠和生物's development of innovative treatments for tumors and autoimmune diseases, particularly through its CC312 pipeline, which has shown promising clinical efficacy [1][2]. - The pre-investment valuation of 惠和生物 was set at 670 million yuan, with the post-investment valuation rising to 738 million yuan [2]. Financial Impact - The investment will not affect the company's daily operations or harm the interests of shareholders, and it is not expected to significantly impact the company's performance in 2025 [3]. - In the third quarter of 2025, the company reported a revenue of 98.55 million yuan, a year-on-year decrease of 6.36%, and a net profit of 3.02 million yuan, down 83.02% [3].

Core Viewpoint - The company has signed investment agreements with multiple parties to acquire a stake in Weihe Bio, focusing on the development of innovative treatments for tumors and autoimmune diseases, aligning with its long-term strategic goals in the healthcare sector [1] Group 1: Investment Details - The company will invest RMB 68 million to subscribe for an increase in registered capital of RMB 175,992 [1] - After the investment, the company will hold a 9.2141% equity stake in Weihe Bio [1] Group 2: Business Focus - Weihe Bio specializes in the development of new treatments for tumor immunity and autoimmune diseases [1] - The company possesses a multi-specific antibody drug design platform [1] Group 3: Strategic Alignment - This investment is a key move for the company to implement its full-chain layout in the autoimmune disease field, covering diagnosis, treatment, and monitoring [1] - The investment aligns with the company's long-term strategy to leverage diagnostic technology advantages to extend into the treatment field, aiming to build comprehensive life and health service capabilities [1]

Core Viewpoint - The investment by the company in Huihe Biotechnology is a strategic move to enhance its presence in the autoimmune disease sector, aligning with its long-term strategy of a comprehensive "diagnosis-treatment-monitoring" approach [1] Investment Details - The company has invested 68 million yuan to acquire a 9.2141% stake in Huihe Biotechnology, which has increased its registered capital by 175,992 yuan [1] - This investment is part of the company's strategy to establish a full-chain layout in the autoimmune disease field [1] Clinical Pipeline - Huihe Biotechnology's main pipeline, CC312, is currently in Phase I clinical trials, which carries the risk of not meeting clinical efficacy expectations [1] - The CC312 pipeline targets systemic lupus erythematosus (SLE) and other autoimmune diseases, addressing significant unmet clinical needs and demonstrating promising research potential [1] - Early clinical studies for the CC312 pipeline have been completed [1]